Skip to content

Author

Kazutaka Oda

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

CYLD: A Key Factor and Novel Predictive Biomarker of Cross-Resistance to Chemotherapy and Radiotherapy in Oral Squamous Cell Carcinoma

Cross-resistance to chemotherapy and radiotherapy is a major obstacle in cancer treatment and strongly associated with poor prognosis. Particularly, oral squamous cell carcinoma (OSCC) frequently exhibits such cross-resistance, limiting the efficacy of standard chemoradiotherapy. To unveil its molecular mechanism, we t...

Kou Yonemaru, Naoki Suenaga, Takeshi Masuda et al. · 0 citations
Open access Aug 2026

Comparison of Two Population Pharmacokinetic Models for Predictive Performance in Vancomycin Therapeutic Drug Monitoring.

Introduction Accurate model-based prediction of vancomycin concentration is essential for therapeutic drug monitoring (TDM); however, the practical criteria for selecting population pharmacokinetic (PopPK) models remain unclear. We compared the predictive performances of the Japanese Oda and Yamamoto PopPK models. Me...

Saki Harada, Kazutaka Oda, Shoji Kondo et al. · 0 citations
Sep 2026

Nonlinear Pharmacokinetic Modeling to Support Clinical Management of Severe Caffeine Intoxication: A Short Communication.

Nonlinear pharmacokinetic modeling successfully characterized caffeine elimination during severe intoxication and provided quantitative estimates of the duration of toxic exposure by providing quantitative estimates of the duration of toxic caffeine exposure.

Kazutaka Oda, Maiko Hori, Fumihiro Nishimura et al. · 0 citations
Aug 2026

Development and validation of machine learning model for selecting the optimal population pharmacokinetic model for vancomycin.

INTRODUCTION Therapeutic drug monitoring (TDM) of vancomycin is recommended based on the area under the concentration-time curve (AUC). The Practical Antimicrobial TDM (PAT) software incorporates two population pharmacokinetic (popPK) models developed by Oda et al. and Yasuhara et al.; however, no objective criteria fo...

H. Akamatsu, Yukinobu Kodama, Ayaka Terai et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.